Sugi Predict
/ Targets
/ MAPK14
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to MAPK14 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma |
PHASE4 | UNKNOWN |
| Anti-oxidative Influence From Pomegranate Tablets on Male Sperm Quality in Couples Undergo Infertility Treatments Due to Male Infertility. |
PHASE3 | UNKNOWN |
| Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome |
PHASE3 | COMPLETED |
| A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma |
PHASE1/PHASE2 | COMPLETED |
| Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
PHASE2 | COMPLETED |
| Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations |
PHASE2 | ACTIVE_NOT_RECRUITING |
| HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma |
PHASE1/PHASE2 | COMPLETED |
| Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer |
PHASE2 | COMPLETED |
| Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer |
PHASE2 | COMPLETED |
| Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer |
PHASE2 | COMPLETED |
| To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. |
PHASE2 | UNKNOWN |
| A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations |
PHASE2 | RECRUITING |
| Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva... |
PHASE2 | COMPLETED |
| Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma |
PHASE2 | UNKNOWN |
| Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant |
PHASE2 | RECRUITING |
| Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas. |
PHASE2 | UNKNOWN |
| A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 |
PHASE1 | COMPLETED |
| Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients |
PHASE1 | UNKNOWN |
| BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab) |
PHASE1 | COMPLETED |
| A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer |
PHASE1 | COMPLETED |
| Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia |
PHASE1 | RECRUITING |
| Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma |
PHASE1 | COMPLETED |
| Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo |
nan | UNKNOWN |
| BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients |
nan | COMPLETED |
| p38 Mitogen-Activated Protein Kinase (MAPK) and Steroid Insensitivity in Asthma |
nan | COMPLETED |
| Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment |
nan | ACTIVE_NOT_RECRUITING |
| Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies |
nan | RECRUITING |
| Biomarkers in Samples From Patients With Endometrial Cancer |
nan | WITHDRAWN |
| Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma |
nan | COMPLETED |
Related proteins — ESM-2 sequence neighbours (a MAPK14 binder may also engage these)